FDAsafety guidance66% confidence
FDA AP — ZEVTERA (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Regeneron; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA218275. Sponsor: ISTX. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEFTOBIPROLE MEDOCARIL SODIUM.
Supporting Context
- Therapeutic area
- Immunology · IL-4/IL-13
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for Dupixent (Dupilumab)